bioRxiv Science⌕ Search

Biology subjects

Blair, J. M.

Publications and source records attributed to Blair, J. M..

2 recordsLinked to original sources

Nutrient-limited conditions reveal the activity of a minor groove binder, MGB-BP-3, against Escherichia coli

BackgroundAntimicrobial resistance demands new antibiotics, but conventional screening in nutrient-rich media often fails to predict in vivo efficacy, especially against Gram-negative bacteria. Minor groove binders (MGB), such as MGB-BP-3, are a promising new antibacterial with potent activity against Gram-positive bacteria but thought to have limited potency against Gram-negative bacteria. ObjectivesThis study evaluated the antibacterial activity of MGB-BP-3 under nutrient-limited, physiologically relevant conditions to better mimic in vivo environments. MethodsMinimum inhibitory concentrations (MICs) were determined against a panel of ESKAPEE pathogens in both rich (Cation Adjusted Mueller-Hinton Broth, CA-MHB) and nutrient-limited media (Roswell Park Memorial Institute, RPMI-1640 + 10% Luria-Bertani, LB). Synergy with efflux pump inhibitors and membrane permeabilizers was evaluated via checkerboard assays. Permeability was assessed using a fluorescent DNA-binding cell permeant (Hoechst 33342) accumulation assay. MICs were determined in the presence of different concentrations of ions, using both wild-type and efflux-compromised strains. In vivo efficacy was assessed using the Galleria mellonella infection model. ResultsThe activity of MGB-BP-3 against Gram-negative bacteria was improved by shifting the medium from rich to nutrient-limited conditions. Specifically, it showed potent activity against E. coli in nutrient-limited media (MIC 3.1 {micro}M) but was inactive in rich media (MIC 700 {micro}M). Synergy with efflux inhibitors occurred mainly in rich media, indicating barriers to intracellular accumulation were not present in nutrient-limited conditions. Increased permeability correlated with enhanced susceptibility and efflux-deficient strains were more susceptible, confirming the role of efflux pumps in resistance. MGB-BP-3 provided dose-dependent protection in G. mellonella larvae infected with E. coli or S. aureus. For example, at concentrations of 12.5 {micro}M and 100 {micro}M, MGB-BP-3 was able to protect the larvae by more than 70% over 5 days of treatment, respectively. ConclusionsNutrient-limited media better reveal MGB-BP-3s activity against Gram-negative bacteria and align with in vivo efficacy, highlighting the need for host-mimicking conditions in antibiotic screening.

microbiology↗

Alginate-based microparticles coated with HPMCP/AS cellulose-derivatives enable the Ctx(Ile21)-Ha antimicrobial peptide application as a feed additive

Microencapsulation is a potential biotechnological tool, which can overcome AMPs instabilities and reduce toxic side effects. Thus, this study evaluates the antibacterial activities of the Ctx(Ile21)-Ha antimicrobial peptide against MDR and non-resistant bacteria, develop and characterize peptide-loaded microparticles coated with HPMCAS and HPMCP. Ctx(Ile21)-Ha microencapsulation was performed by ionic gelation with high-efficiency, maintaining the physical-chemical stability. Ctx(Ile21)-Ha coated-microparticles were characterized, and their hemolytic activity assay demonstrated that hemolysis was decreased up to 95% compared to single molecule. In addition, in vitro release control profile simulating different portions of gastrointestinal tract was performed and showed the microcapsules ability to protect the peptide and release it in the intestine, aimed pathogens location, mainly by Salmonella sp. Therefore, use of microencapsulated Ctx(Ile21)-Ha can be allowed as an antimicrobial controller in monogastric animal production, being a valuable option for molecules with low therapeutic indexes or high hemolytic rates.

biochemistry↗